© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Feb 28, 2015, the consensus forecast amongst 37 polled investment analysts covering AstraZeneca plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jul 31, 2009. The previous consensus forecast advised that AstraZeneca plc would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
Share price forecast information is not available for AstraZeneca PLC. View Full Financials
In 2014, AstraZeneca PLC reported a dividend of 2.80 USD, equaling last years dividend. The 28 analysts covering the company expect dividends of 2.80 USD for the upcoming fiscal year, maintaining dividends from this year. View Full Financials
|Div growth (TTM)||0.00%|
On Feb 05, 2015, AstraZeneca plc reported 4th quarter 2014 earnings of 0.76 per share. This result under-performed the 0.82 consensus expectations of the 11 analysts following the company but under-performed last year's 4th quarter results by 38.21%.
The next earnings announcement is expected on Apr 24, 2015. View Full Interim Financials
|Average growth rate||-10.15%|
AstraZeneca plc reported annual 2014 earnings of 4.28 per share on Feb 05, 2015. View Full Annual Financials
|Average growth rate||-9.98%|
AstraZeneca PLC had 4th quarter 2014 revenues of 6.683bn. This missed the 6.768bn consensus estimate of the 14 analysts following the company. This was 2.16% above the prior year's 4th quarter results. View Full Interim Financials
|Average growth rate||-0.54%|
AstraZeneca PLC had revenues for the full year 2014 of 26.095bn. This was 1.49% above the prior year's results. View Full Annual Financials
|Average growth rate||-5.59%|